

Recruiting to the BSR Biologics Register for Rheumatoid Arthritis (BSRBR-RA)

All registrations (both participants new to the study and those being re-registered to a new cohort) will count towards UK CRN accrual data. **UK CRN ID: 7302.**

Drug	Biologic/Other targeted therapy Naïve?	Other Details
Inflectra (Infliximab)	<p>No* (*does not need to be biologic/other targeted therapy naïve)</p>	<p>Open to new registrations and existing participants who switch to a biosimilar (including a switch from any biologic/targeted therapy).</p>
Remsima (Infliximab)		
Flixabi (Infliximab)		
Benepali (Etanercept)		
Erelzi (Etanercept)		
Rixathon (Rituximab)		
Cimzia (Certolizumab)	No*	Open to new registrations and existing participants who start Cimzia.
Actemra/RoActemra (Tocilizumab)	No*	Open to new registrations and existing participants who start Actemra/RoActemra or Kevzara.
Kevzara (Sarilumab)		
Olumiant (Baricitinib)	No*	Open to new registrations and existing participants who start Olumiant or Xeljanz.
Xeljanz (Tofacitinib)		
Humira (Adalimumab)	<p>Yes Must not have previously received biologic/other targeted therapy</p>	Referred to as the 'Anti-TNF comparison cohort'.
Enbrel (Etanercept)		
Remicade (Infliximab)		

Registration forms available at www.bsrbr.org

New participants must be registered with us within approx. 6 months of first dose date. Follow up of all participants continues even if therapy is switched/discontinued.